X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
anilides - pharmacology (2578) 2578
animals (1952) 1952
humans (1847) 1847
male (1468) 1468
mice (775) 775
rats (756) 756
pharmacology & pharmacy (657) 657
female (649) 649
cell line, tumor (483) 483
anilides - therapeutic use (479) 479
oncology (359) 359
dose-response relationship, drug (351) 351
anilides - chemistry (347) 347
biochemistry & molecular biology (327) 327
antineoplastic agents - pharmacology (314) 314
androgen antagonists - pharmacology (301) 301
expression (301) 301
ppar gamma - antagonists & inhibitors (301) 301
pyridines - pharmacology (298) 298
ppar gamma - metabolism (292) 292
structure-activity relationship (289) 289
middle aged (280) 280
anilides - chemical synthesis (267) 267
anilides - administration & dosage (263) 263
chemistry, medicinal (261) 261
cells, cultured (258) 258
anilides (256) 256
nitriles - pharmacology (248) 248
signal transduction - drug effects (248) 248
cancer (243) 243
cell proliferation - drug effects (242) 242
anilides - metabolism (234) 234
tosyl compounds - pharmacology (234) 234
prostate cancer (230) 230
prostatic neoplasms - drug therapy (225) 225
nitriles (224) 224
time factors (224) 224
tosyl compounds (224) 224
receptors, androgen - metabolism (218) 218
adult (211) 211
apoptosis (205) 205
activation (204) 204
aged (203) 203
in vitro techniques (203) 203
rats, sprague-dawley (199) 199
cell biology (198) 198
thiazolidinediones - pharmacology (198) 198
research (194) 194
prostatic neoplasms - metabolism (178) 178
anilides - pharmacokinetics (177) 177
apoptosis - drug effects (177) 177
prostatic neoplasms - pathology (177) 177
disease models, animal (176) 176
flutamide - pharmacology (174) 174
dogs (172) 172
signal transduction (170) 170
cell line (168) 168
kinetics (166) 166
analysis (164) 164
endocrinology & metabolism (157) 157
pyridines - therapeutic use (157) 157
ppar gamma - agonists (155) 155
anilides - adverse effects (154) 154
ligands (154) 154
ppar-gamma (152) 152
enzyme inhibitors - pharmacology (151) 151
antineoplastic agents - therapeutic use (149) 149
neurosciences (149) 149
growth (144) 144
mice, inbred c57bl (144) 144
pharmacology (144) 144
androgen receptor (142) 142
gene expression (141) 141
proteins (140) 140
cell survival - drug effects (139) 139
bicalutamide (136) 136
cinnamates - pharmacology (136) 136
cells (135) 135
inhibition (135) 135
blotting, western (131) 131
molecular structure (131) 131
in-vitro (126) 126
chemistry (124) 124
rabbits (121) 121
inflammation (120) 120
encainide (119) 119
receptors, androgen - genetics (118) 118
toxicology (118) 118
rats, wistar (117) 117
therapy (116) 116
ppar gamma - genetics (115) 115
mutation (112) 112
urology & nephrology (110) 110
xenograft model antitumor assays (109) 109
phosphorylation (108) 108
administration, oral (107) 107
guinea pigs (106) 106
research article (106) 106
rna, messenger - metabolism (105) 105
chemistry, organic (102) 102
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3395) 3395
German (111) 111
Japanese (53) 53
Italian (32) 32
Russian (27) 27
Chinese (23) 23
French (17) 17
Ukrainian (8) 8
Polish (7) 7
Spanish (5) 5
Czech (4) 4
Hungarian (2) 2
Portuguese (2) 2
Croatian (1) 1
Dutch (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of the National Cancer Institute, ISSN 0027-8874, 11/2011, Volume 103, Issue 22, pp. 1665 - 1675
Recent advances in tumor biology have made remarkable achievements in the development of therapy for metastatic castrate-resistant prostate cancer. These... 
GROWTH-FACTOR RECEPTOR | CONTROLLED-TRIAL | ANTIANGIOGENIC THERAPY | ONCOLOGY | RANDOMIZED PHASE-II | BONE METASTASES | C-MET | SIPULEUCEL-T APC8015 | ABIRATERONE ACETATE | TUMOR MICROENVIRONMENT | ANGIOGENESIS INHIBITION | Cancer Vaccines - pharmacology | Humans | Male | Antineoplastic Agents - therapeutic use | Bevacizumab | Prostatic Neoplasms - immunology | RANK Ligand - pharmacology | Receptors, Androgen - drug effects | Treatment Failure | Prostatic Neoplasms - drug therapy | Phenylthiohydantoin - pharmacology | Tumor Microenvironment - drug effects | Dasatinib | Antibodies, Monoclonal - pharmacology | Angiogenesis Inhibitors - pharmacology | Clusterin - pharmacology | Pyrimidines - pharmacology | Denosumab | Prostate-Specific Antigen - blood | Orchiectomy | Signal Transduction - drug effects | Anilides - pharmacology | Mice | Receptor Cross-Talk - drug effects | Endothelin-1 - antagonists & inhibitors | Immunotherapy - methods | Taxoids - pharmacology | Ipilimumab | Tissue Extracts - pharmacology | Bone Remodeling - drug effects | Pyrrolidines - pharmacology | Antibodies, Monoclonal, Humanized - pharmacology | Indoles - pharmacology | Antineoplastic Agents - pharmacology | Molecular Targeted Therapy - methods | Prostatic Neoplasms - pathology | Antineoplastic Agents, Hormonal - pharmacology | Androstenols - pharmacology | Androstenes | Clinical Trials as Topic | Mice, SCID | Phenylthiohydantoin - analogs & derivatives | Biomarkers, Tumor - blood | Xenograft Model Antitumor Assays | Cancer Vaccines - immunology | Pyrroles - pharmacology | Animals | RANK Ligand - antagonists & inhibitors | Pyridines - pharmacology | Thiazoles - pharmacology | Immune response | Development and progression | Cellular signal transduction | Research | Drug therapy | Health aspects | Prostate cancer | Risk factors | Review
Journal Article
Nature medicine, ISSN 1546-170X, 2016, Volume 22, Issue 2, pp. 194 - 201
Journal Article
Journal Article
Journal of Biological Chemistry, ISSN 0021-9258, 07/2014, Volume 289, Issue 30, pp. 21082 - 21097
Journal Article
Cancer discovery, ISSN 2159-8290, 2014, Volume 4, Issue 7, pp. 816 - 827
Journal Article
Journal Article
Neuroscience, ISSN 0306-4522, 2011, Volume 193, pp. 440 - 451
Abstract Paclitaxel chemotherapy is limited by a long-lasting painful neuropathy that lacks an effective therapy. In this study, we tested the hypothesis that... 
Neurology | mast cell tryptase | paclitaxel-induced pain | TRPV1 | TRPA1 | proteinase-activated receptor 2 | TRPV4 | Proteinase-activated receptor 2 | Mast cell tryptase | Paclitaxel-induced pain | NEUROSCIENCES | SENSORY NEURONS | CAPSAICIN RECEPTOR | MECHANICAL HYPERALGESIA | IN-VIVO | KINASE-C-EPSILON | ION-CHANNEL | PERIPHERAL NEUROPATHY | INFLAMMATORY PAIN | PROTEASE-ACTIVATED-RECEPTOR-2 SENSITIZES | IRRITABLE-BOWEL-SYNDROME | Tryptases - metabolism | Central Nervous System - metabolism | Capsaicin - pharmacology | Receptor, PAR-2 - metabolism | Type C Phospholipases - metabolism | Male | Neuralgia - pathology | Dose-Response Relationship, Drug | TRPV Cation Channels - metabolism | Receptor, PAR-2 - antagonists & inhibitors | Drug Interactions | Paclitaxel - toxicity | Time Factors | Protein Kinase C - metabolism | TRPV Cation Channels - antagonists & inhibitors | Estrenes - pharmacology | Pyrrolidinones - pharmacology | Neuralgia - chemically induced | Neuralgia - physiopathology | Disease Models, Animal | Cyclic AMP-Dependent Protein Kinases - metabolism | Enzyme Inhibitors - pharmacology | Capsaicin - analogs & derivatives | Sulfonamides - pharmacology | Cinnamates - pharmacology | Mice, Inbred ICR | Hyperalgesia - physiopathology | Antineoplastic Agents, Phytogenic - toxicity | Gene Expression Regulation - drug effects | Pain Measurement - methods | Pyrroles - pharmacology | Animals | Analysis of Variance | Ankyrins - antagonists & inhibitors | Anilides - pharmacology | Ankyrins - metabolism | Central Nervous System - drug effects | Mice | Physical Stimulation - adverse effects | Carbazoles - pharmacology | Oligopeptides - pharmacology | Protein Kinase C - pharmacology | Enzymes | Care and treatment | Neurosciences | Paclitaxel | Phospholipases | Protein kinases | Cancer
Journal Article
Neuropsychopharmacology (New York, N.Y.), ISSN 1740-634X, 2008, Volume 34, Issue 3, pp. 593 - 606
Journal Article
British Journal of Pharmacology, ISSN 0007-1188, 08/2011, Volume 163, Issue 7, pp. 1533 - 1549
BACKGROUND AND PURPOSE Endocannabinoids have both anti‐inflammatory and neuroprotective properties against harmful stimuli. We previously demonstrated that the... 
monoacylglycerol lipase | peroxisome proliferator‐activated receptor‐γ | nuclear factor κ‐B | endocannabinoids | neuroinflammation | cyclooxygenase‐2 | nuclear factor κ-B | peroxisome proliferator-activated receptor-γ | cyclooxygenase-2 | CB1 CANNABINOID RECEPTORS | 2-ARACHIDONYL GLYCEROL | NUCLEAR RECEPTORS | SYNAPTIC-TRANSMISSION | MICROGLIAL CELLS | KAPPA-B | OXIDATIVE-METABOLISM | peroxisome proliferator-activated receptor-gamma | PROTECTS NEURONS | nuclear factor kappa-B | ACTIVATED-RECEPTOR-GAMMA | PHARMACOLOGY & PHARMACY | Cannabinoid Receptor Modulators - pharmacology | Interleukin-1beta - pharmacology | Monoacylglycerol Lipases - antagonists & inhibitors | NF-kappa B - metabolism | Hippocampus - drug effects | PPAR gamma - metabolism | Excitatory Postsynaptic Potentials - drug effects | Cyclooxygenase 2 - biosynthesis | Inflammation - metabolism | Biphenyl Compounds - pharmacology | Piperidines - pharmacology | Cyclooxygenase 2 - genetics | Prostaglandin D2 - analogs & derivatives | Synaptic Transmission - drug effects | Neurons - metabolism | Phosphorylation - drug effects | Neurons - drug effects | Thiazolidinediones - pharmacology | Endocannabinoids | PPAR gamma - genetics | NF-kappa B - antagonists & inhibitors | Cyclooxygenase 2 Inhibitors - pharmacology | Cells, Cultured | Arachidonic Acids - pharmacology | Hippocampus - metabolism | Receptor, Cannabinoid, CB1 - metabolism | Glycerides - pharmacology | Animals | PPAR gamma - antagonists & inhibitors | Signal Transduction - drug effects | Anilides - pharmacology | Cyclooxygenase 2 - metabolism | Lipopolysaccharides - pharmacology | PPAR gamma - agonists | Mice | Prostaglandin D2 - pharmacology | Receptor, Cannabinoid, CB1 - antagonists & inhibitors | Benzodioxoles - pharmacology | Research Papers
Journal Article
Journal Article
Journal Article
British journal of pharmacology, ISSN 0007-1188, 2015, Volume 172, Issue 1, pp. 24 - 37
Background and Purpose N-docosahexaenoylethanolamine (DHEA) is the ethanolamine conjugate of the long-chain polyunsaturated n-3 fatty acid docosahexaenoic... 
arrive guidelines | pharmacology | fatty-acids | cannabinoid receptor | prostaglandin e-2 | nitric-oxide synthase | anandamide | fish-oil | concise guide | kappa-b | PLASMA | CONCISE GUIDE | NITRIC-OXIDE SYNTHASE | INFLAMMATION | OXYGENATION | ANANDAMIDE | PHARMACOLOGY & PHARMACY | FATTY-ACIDS | FISH-OIL | KAPPA-B | ETHANOLAMIDE | Endocannabinoids - metabolism | Bornanes - pharmacology | Male | NF-kappa B - metabolism | Receptor, Cannabinoid, CB2 - antagonists & inhibitors | PPAR gamma - metabolism | Piperidines - pharmacology | Thiazolidinediones - pharmacology | Pyrazoles - pharmacology | Cell Line | Indenes - pharmacology | Cyclooxygenase 2 Inhibitors - pharmacology | Dehydroepiandrosterone - pharmacology | Mice, Inbred C57BL | Cells, Cultured | Toll-Like Receptor 3 - metabolism | Toll-Like Receptor 4 - metabolism | Arachidonic Acids - pharmacology | Mice, Knockout | Dinoprostone - metabolism | Receptor, Cannabinoid, CB1 - metabolism | Receptor, Cannabinoid, CB2 - metabolism | Macrophages - metabolism | Animals | PPAR gamma - antagonists & inhibitors | Interferon-beta - metabolism | Anilides - pharmacology | Cyclooxygenase 2 - metabolism | Lipopolysaccharides - pharmacology | Macrophages - drug effects | Mice | Receptor, Cannabinoid, CB1 - antagonists & inhibitors | Nitric Oxide - metabolism | Myeloid Differentiation Factor 88 - metabolism | Androgens | Dehydroepiandrosterone | DNA microarrays | Anti-inflammatory drugs | RNA | Ethanolamines | Macrophages | Gene expression | Fatty acids | Medical research | Rodents | Research Papers
Journal Article